Integrating Radiomics and Genomics to Improve the Clinical Assessment of Pancreatic Cysts and Early Detection of Pancreatic Cancer
Abstract
With the rapid utilization and ongoing advancements in cross-sectional abdominal imaging, the detection of pancreatic cysts has become increasingly frequent. It is reported pancreatic cysts are identified in 1.2-2.6 percent of abdominal computed tomography (CT) scans. Many of these cysts, including serous cystadenomas (SCA) and pseudocysts, are benign and can be monitored clinically. In contrast, mucinous cysts, which include intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), have the potential to progress to pancreatic adenocarcinoma (PDAC). Currently, a multidisciplinary approach is recommended in the assessment of pancreatic cysts. This includes clinical and radiographic evaluation, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), cytology, cyst fluid analysis (e.g., viscosity) and tumor markers (e.g., carcinoembryonic antigen (CEA)). Despite a combination of methodologies, the distinction between mucinous cysts from other pancreatic cysts can be difficult. Moreover, the detection of PDAC within a pancreatic cyst can be even more challenging. Thus, there is a dire need for biomarker assays that can accurately differentiate mucinous from non mucinous pancreatic cysts and the presence versus absence of advanced neoplasia within a pancreatic cyst. This proposal represents the formation of a multi-institutional team of investigators to evaluate promising radiomic and genomic biomarkers to improve the initial evaluation and follow-up for patients with pancreatic cysts.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2022
- Accession Number
- AD1191052
Entities
People
- Randall E Brand
Organizations
- University of Pittsburgh